CHEST 2019
Home Oxygen Use Associated With Worsened Physical Function in COPD and IPF
Use of home oxygen is associated with reduced physical function in patients with either COPD or idiopathic pulmonary fibrosis.
Your search for supplemental oxygen returned 48 results
ESC 2017
Does Oxygen Therapy Reduce Mortality in Suspected Acute MI?
Routine use of supplemental oxygen does not reduce one-year all-cause mortality versus ambient air
News
Oxygen Therapy for Mild COPD: Is It Beneficial?
Researchers find oxygen therapy does not improve quality of life, forestall hospitalization, lengthen lives
Drugs in the Pipeline
NIH: Remdesivir Plus Interferon Beta-1a Being Evaluated for COVID-19
The placebo-controlled ACTT 3 trial will evaluate the efficacy and safety of remdesivir in combination with interferon beta-1a in more than 1000 hospitalized COVID-19 patients.
News
Intravenous Vitamin C Linked to Early Recovery in Critically Ill COVID-19 Patient
The patient, a 74-year-old female, presented to the ER after experiencing a low grade fever, cough, and shortness of breath for 2 days.
News
Steroid May Reduce COVID-19 Death Risk by Up to One-Third
Dexamethasone appears promising for patients with severe illness.
Drugs in the Pipeline
Early Data Show Potential Benefit of Acalabrutinib in Severe COVID-19
Acalabrutinib, a Bruton tyrosine kinase (BTK) inhibitor, appears to reduce respiratory distress as well as the hyperinflammatory immune response associated with coronavirus disease 2019.
News
Five-Day Course of Remdesivir Beneficial in Severe COVID-19
No significant difference seen in five-, 10-day course for severe COVID-19 without mechanical ventilation.
News
Remdesivir Improves Time To Recovery for Patients Hospitalized With COVID-19
Treatment with remdesivir was associated with a shorter time to recovery in patients hospitalized with coronavirus disease 2019 (COVID-19), according to peer-reviewed data published in the New England Journal of Medicine.
Drugs in the Pipeline
Antiviral Merimepodib to Be Investigated in Phase 2 Trial for COVID-19
Following clearance of an Investigational New Drug Application by the Food and Drug Administration, ViralClear announced that a phase 2 study evaluating merimepodib oral solution for the treatment of coronavirus disease 2019 (COVID-19) will be initiated.
